Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 29, 2010 FBO #3231
DOCUMENT

A -- Gene Targeting Services - Justification and Approval (J&A)

Notice Date

9/27/2010
 

Notice Type

Justification and Approval (J&A)
 

NAICS

541711 — Research and Development in Biotechnology
 

Contracting Office

Department of Veterans Affairs;VISN 22 Network Contracting Activity;Building 149;5901 E. 7th Street;Long Beach CA 90822
 

ZIP Code

90822
 

Solicitation Number

VA26210RQ0484
 

Response Due

9/17/2010
 

Archive Date

11/16/2010
 

Point of Contact

Jan Smith
 

E-Mail Address

SS<br
 

Small Business Set-Aside

N/A
 

Award Number

VA664-D05155
 

Award Date

9/14/2010
 

Description

DEPARTMENT OF VETERANS AFFAIRS VISN 22 NETWORK CONTRACTING ACTIVITY JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION FAR 6.302-1, 41 U.S.C. 253 (c) (1) 1. Agency and Contracting Activity Identification: The Department of Veterans Affairs VISN 22 Network Contracting Activity has a requirement for gene targeting services for custom conditional targeting for 5033414D02Rik Transmembrane protein C9orf46 homolog for VA San Diego Healthcare System as described in transaction number 664-10-3-143-1303. 2. Nature of Acquisition Being Approved: To procure services from inGenious Targeting Laboratory, Inc. on a sole source basis. 3. Description of Supplies or Services to Meet Agency Needs: (1) Cloning and construction of targeting vector for hybrid 129S6/SvEvTac/C57BL/6 cell line, including analysis of gene structure, screening strategy design, probe design, isolation and confirmation of genomic BAC clone, targeting vector construction including insertion and confirmation of homology arms, flanking of the genomic targeting region by Lox-P sites for Cre-excision, insertion and confirmation of Neomycin selection cassette flanked by FRT sites for positive selection, and preparation of DNA for electroporation. (2) Electroporation of hybrid 129S6/SvEvTac/C57BL/6 ES cells with targeting vector and tissue culture work to isolate antibiotic-resistant clones, and (3) Screening of ES cell clones to identify positives, including preparation of DNA from individual ES clones and confirmation of targeting events by PCR and Southern Blotting. 4. Statutory Authority Permitting Other Than Full and Open Competition: Contracting without providing for full and open competition is authorized by Citation 41 U.S.C. 253(c)(1), and by FAR 6.302-1 - Only One Responsible Source and no Other Supplies or Services will Satisfy Agency Requirements. 5. Demonstration of the Proposed Contractor's Unique Qualifications or the Nature of the Acquisition Requires Use of the Authority Cited: The inGenious Targeting Laboratory is the only vendor that offers all of the above specific services required. In addition, the inGenious Targeting Laboratory developed the Hybrid ES cell technology, creating a new line (129S6/SVEvTac strain with the C57BL/6 line) and is the only vendor to offer electroporation into this line. Dr. Parmer's research project already has been collecting data involving this Hybrid (129S6/SvEvTac/C57BL/6) cell line. Thus, it is essential that the Research department continue using this specific cell line in order to be able to interpret the new information in conjunction with their previous and ongoing data collection. In addition, use of this hybrid cell line dramatically increases efficiency of homologous recombination when compared to other cell lines. Also, inGenious Targeting Laboratory guarantees a result or they don't charge a fee. 6. A Description of Efforts Made to Ensure That Offers Are Solicited From as Many Potential Sources as is Practicable and Whether a Notice Will Be Publicized: This requirement will be advertised as an intent to solicit and negotiate with only one source under the authority of 6.302, as required by FAR 5.203 7. Determination Anticipated Cost Will Be Fair and Reasonable: Prices, when compared to Jefferson Kimmel Cancer Center for similar, but not exact services, are within a comparable range for these commercial services. Per Dr. Parmer, who has worked with several different laboratories, has stated that the prices are competitive and fair. 8. Description and Results of Market Research or Statement why Market Research Was Not Conducted: A search of the GSA e-library produced no results. A search of the CCR using NAICS code 541711 - Research and Development in Biotechnology and the keywords, "gene targeting" produced no results. A Google search produced several sources, but after reading several individual company profiles, 3 sources seemed the most likely to have the capabilities to provide the required services. They are as follows: (1) University of California Irvine (UCI), (2) Jefferson Kimmel Cancer Center, and (3) University of Pennsylvania. Due to the complexity of the technical information that is provided in Dr. Parmer's 2237, the Contracting Officer requested that Dr. Parmer contact the 3 sources and talk to one of their scientists to see if they could provide the same technical services that Dr. Parmer needs to continue his ongoing research. Dr. Parmer contacted Mr. Tom Fielder at UCI (949) 824-6496, Mr. Carlisle Landel, Ph.D. at the Jefferson Kimmel Cancer Center (215) 503-4539, and another person (Dr. Parmer forgot the person's name) at the University of Pennsylvania, Penn Medicine (215) 573-9327. Dr. Parmer's findings are as follows: None of the 3 vendors were able to provide the exact services required. Cloning and construction of the targeting vector, as outlined in item #3(1) above, is not provided. In addition, none of the facilities uses the specific Hybrid (129S6/SvEvTac/C57BL/6) ES cell line required. Also, the required screening services as outlined in item #3(3) above, is not provided. Finally, none of the 3 vendors guarantee a result. 9. Any Other Facts Supporting the Use of Other Than Full and Open Competition: Although there are companies available that do like services, the VA Research Investigator, Dr. Parmer has already been collecting data involving this new Hybrid cell line. If a different cell line is used at this stage of the research, it would not be able to be properly or accurately interpreted in conjunction with his previous and ongoing data collection. This would jeopardize the validity of Dr. Parmer's study. 10. List Any Other Sources That Expressed Interest in Writing? No sources have expressed an interest, in writing, in this acquisition. However, an FBO announcement announcing our intent to negotiate a sole source procurement will be publicized. 11. A Statement of the Actions, if any, the Agency May Take To Remove of Overcome Any Barriers to Competition Before Any Subsequent Acquisition is required: 12. I hereby certify that the above is accurate and complete to the best of my knowledge and belief. Jan Smith Contracting Officer/Specialist Name9/01/2010 Medical Support Section(Date)
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/LBVANBC/VAMD/VA26210RQ0484/listing.html)
 

Document(s)

Justification and Approval (J&A)
 

File Name: VA664-D05155 VA664-D05155_1.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=159100&FileName=-419.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=159100&FileName=-419.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Record

SN02297722-W 20100929/100927234417-5f2d321e72cf65ce56e28f0a3eb073c7 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |